The Market Herald: Optimi Health Corp (CSE:OPTI) signs psilocybin supply agreement with Filament Health (NEO:FH)

By Azuka Onwuka

 

 

Optimi Health Corp (OPTI) has signed a supply agreement with Filament Health, a clinical-stage natural psychedelic drug development company.

Filament has engaged Optimi to supply psilocybin mushrooms cultivated in Optimi’s recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia, facility to produce whole, dried mushroom fruiting bodies for potential drug development and analysis by Filament’s research team.

“Our supply agreement with Filament Health is an excellent fit for both parties,” stated Optimi CEO Bill Ciprick.

“Filament’s commitment to developing unique intellectual properties using natural psychedelic medicines and the advancement of natural psilocybin in the space as a whole is well-aligned with our values and goals for the future of psychedelics,” he added.

“We are pleased to partner with Optimi as we build out our own supply chain and explore external suppliers,” noted Filament Health CEO and Co-Founder Benjamin Lightburn.

“This is an important step for Filament, and we look forward to determining the compatibility of Optimi’s product with our industry-leading natural extraction technology,” he added.

The two companies believe that the agreement sends a strong message that safety and research are paramount to growing a safe and secure supply of natural psilocybin.

Optimi Health Corp. is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Filament Health is a clinical-stage natural psychedelic drug development company.

Optimi Health Corp. (OPTI) opened trading at $0.35.

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.